Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
Sponsor: Unity Health Toronto
Summary
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-11-27
Completion Date
2027-09
Last Updated
2026-06-26
Healthy Volunteers
No
Interventions
Semaglutide Pen
Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.
Locations (2)
Unity Health Toronto
Toronto, Ontario, Canada
Unity Health Toronto
Toronto, Ontario, Canada